Complicated Intra-Abdominal Infection Clinical Trial
Official title:
The Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial antibiotic empiric therapy on pharmacological and total healthcare costs for these patients in Greece.
Every patient diagnosed with complicated intra-abdominal infections will enter the study, until the pre-specified number of patients is reached. Patients diagnosed with any of conditions mentioned below (inclusion criteria) will enter the study, until the pre-specified number of patients is reached. ;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05905055 -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
|
Phase 3 | |
| Completed |
NCT03293485 -
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
|
Phase 3 | |
| Recruiting |
NCT05148702 -
EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.
|
Phase 3 | |
| Completed |
NCT04927312 -
Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection
|
Phase 3 | |
| Completed |
NCT01499290 -
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
|
Phase 3 | |
| Completed |
NCT01147640 -
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
|
Phase 2 | |
| Completed |
NCT01644643 -
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
|
Phase 3 | |
| Completed |
NCT01726023 -
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
|
Phase 3 | |
| Withdrawn |
NCT01602874 -
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT01265784 -
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
|
Phase 2 | |
| Withdrawn |
NCT00914888 -
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
|
Phase 3 | |
| Completed |
NCT00157898 -
A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)
|
Phase 4 | |
| Recruiting |
NCT05733104 -
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
|
||
| Completed |
NCT01445678 -
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
|
Phase 3 | |
| Completed |
NCT02739997 -
Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
|
Phase 3 | |
| Completed |
NCT03329092 -
A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
|
Phase 3 | |
| Completed |
NCT03217136 -
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
|
Phase 2 | |
| Completed |
NCT01500239 -
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections
|
Phase 3 |